Regular Blood Transfusion Does Not Prevent Progression of Cerebral Lesions Evidenced by Magnetic Resonance Imaging in Children with Sickle Cell Disease (SCD).

Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 792-792
Author(s):  
Valentine Brousse ◽  
Lucie Hertz-Pannier ◽  
Jean-Louis Bresson ◽  
Mariane De Montalembert

Abstract Purpose: The effects of chronic transfusion on the cerebral vessel abnormalities in SCD patients are unknown. Chronic transfusion has been reported to be effective in preventing recurrence of overt strokes, and occurrence of a first stroke in children with abnormal transcranial Doppler ultrasonography (TCD). However, cerebrovascular events may occur despite adequate prevention, suggesting that transfusion therapy does not cure nor even stabilize vessels disease. We conducted a single center retrospective study to determine the evolution of cerebral lesions in SCD children on regular transfusion therapy using magnetic resonance imaging. Material and methods: Children with homozygous sickle cell anemia chronically transfused for first or secondary prevention of stroke were included in the study. All patients had been started in a program of monthly transfusions, maintaining constantly hemoglobin S level below 30%, in the month following the stroke or the abnormal TCD. They underwent cerebral magnetic resonance imaging (MRI) and magnetic resonance angiography (MRA) every one to two years. An expert neuroradiologist unaware of the date of the imaging and unaware of the identity of the patients reviewed resulting images. Standard MRI criteria were used to identify lacunae, cerebral atrophy, infarcts and leucoencephalopathy, with progressive grading. Standard MRA criteria were used to identify arterial tortuosity, stenosis/occlusion and moya-moya with progressive grading. All MRI and MRA were scored, and these scores were compared longitudinally in each patient using a Paired Rank test. Results: 18 children (9 males, 9 females) were enrolled. Chronic transfusion therapy was prescribed and initiated for 10 patients with initial strokes (mean age at the stroke 6,8 +/− 2,5 yrs) and 8 patients with abnormal TCD (mean age at the TCD 7,2 +/− 2,9 yrs). Mean follow-up was 6,8 +/− 4,1 yrs in the stroke group, 1,7 +/− 1,0 yrs in the abnormal TCD group. A total of 45 MR images were reviewed (median MR/patient: 3 [2–4]). Initial scores were lower in the abnormal TCD group than in the stroke group (mean score respectively 1 [0–7] versus 12 [2–26]). Comparison of longitudinal scores in the group of patients with initial stroke evidenced progression of lesions (p=0,008). The longitudinal scores were not significantly different in the abnormal TCD group, but this may be explained by the shorter follow-up. Conclusion: Blood transfusion maintaining permanently HbS level <30% does not prevent progression of cerebral micro or macro vascular lesions in SCD children having had a 1st stroke. A lengthier follow-up is needed to reach a conclusion in the case of children with abnormal TCD. Our results support the case that early bone marrow transplant therapy should be applied to prevent progression of cerebral vasculopathy in SCD children at risk.

Heart Rhythm ◽  
2011 ◽  
Vol 8 (11) ◽  
pp. 1705-1711 ◽  
Author(s):  
Thomas Deneke ◽  
Dong-In Shin ◽  
Osman Balta ◽  
Kathrin Bünz ◽  
Frank Fassbender ◽  
...  

Neurosurgery ◽  
2006 ◽  
Vol 58 (6) ◽  
pp. 1081-1089 ◽  
Author(s):  
John Sinclair ◽  
Steven D. Chang ◽  
Iris C. Gibbs ◽  
John R. Adler

Abstract OBJECTIVE: Intramedullary spinal cord arteriovenous malformations (AVMs) have an unfavorable natural history that characteristically involves myelopathy secondary to progressive ischemia and/or recurrent hemorrhage. Although some lesions can be managed successfully with embolization and surgery, AVM size, location, and angioarchitecture precludes treatment in many circumstances. Given the poor outlook for such patients, and building on the successful experience with radiosurgical ablation of cerebral AVMs, our group at Stanford University has used CyberKnife (Accuray, Inc., Sunnyvale, CA) stereotactic radiosurgery (SRS) to treat selected spinal cord AVMs since 1997. In this article, we retrospectively analyze our preliminary experience with this technique. METHODS: Fifteen patients with intramedullary spinal cord AVMs (nine cervical, three thoracic, and three conus medullaris) were treated by image-guided SRS between 1997 and 2005. SRS was delivered in two to five sessions with an average marginal dose of 20.5 Gy. The biologically effective dose used in individual patients was escalated gradually over the course of this study. Clinical and magnetic resonance imaging follow-up were carried out annually, and spinal angiography was repeated at 3 years. RESULTS: After a mean follow-up period of 27.9 months (range, 3–59 mo), six of the seven patients who were more than 3 years from SRS had significant reductions in AVM volumes on interim magnetic resonance imaging examinations. In four of the five patients who underwent postoperative spinal angiography, persistent AVM was confirmed, albeit reduced in size. One patient demonstrated complete angiographic obliteration of a conus medullaris AVM 26 months after radiosurgery. There was no evidence of further hemorrhage after CyberKnife treatment or neurological deterioration attributable to SRS. CONCLUSION: This description of CyberKnife radiosurgical ablation demonstrates its feasibility and apparent safety for selected intramedullary spinal cord AVMs. Additional experience is necessary to ascertain the optimal radiosurgical dose and ultimate efficacy of this technique.


Sign in / Sign up

Export Citation Format

Share Document